AOD-9604: Peptide Profile, CAS & Properties
CAS 221231-10-3 · 1815.10 g/mol
AOD-9604 (CAS 221231-10-3) is a synthetic 16-amino-acid peptide derived from the C-terminal lipolytic region of human growth hormone, classed as a modified hGH(176-191) fragment. Its molecular weight is about 1815.10 g/mol. It is not approved by the FDA, EMA or other major regulators for therapeutic use. This page provides reference information on AOD-9604.
- CAS Number
- 221231-10-3
- Molecular Formula
- C78H123N23O23S2
- Molecular Weight
- 1815.10 g/mol
- Drug Class
- modified hGH(176-191) fragment
What is AOD-9604?
AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal lipolytic region of human growth hormone — the hGH(177-191) fragment with an additional tyrosine residue at the N-terminus (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe). The two cysteine residues form a single intramolecular disulfide bond. Its CAS number is 221231-10-3, with molecular formula C78H123N23O23S2 and a molecular weight of approximately 1815.10 g/mol.
Mechanistically, AOD-9604 has been studied in vitro and in preclinical models as a modulator of adipocyte fat metabolism, where it has been reported to stimulate lipolysis and reduce lipogenesis without the carbohydrate-metabolism effects (such as changes in blood glucose, insulin sensitivity or IGF-1) associated with full-length growth hormone. Importantly, AOD-9604 is not approved by the FDA, EMA or other major regulators for therapeutic use; clinical development as an anti-obesity agent did not lead to approval.
How AOD-9604 Is Produced & Characterised
AOD-9604 is a disulfide-bridged hexadecapeptide, and its production carries the usual short-peptide challenges: complete coupling of each residue, correct regioselective formation of the single Cys-Cys disulfide bond, and avoidance of scrambled or dimeric by-products. The peptide is generally prepared by Fmoc solid-phase peptide synthesis (SPPS), followed by controlled oxidative folding to set the correct disulfide, then purification on preparative dynamic axial compression (DAC) HPLC columns to resolve the target sequence from deletion sequences and disulfide isomers, and lyophilisation to a stable, uniform powder.
Analytical characterisation of a peptide of this class typically combines UPLC/HPLC for purity determination with LC-MS to confirm the sequence and to profile minor structural variants such as disulfide isomers and deletion sequences. This is the general industry approach for short, cysteine-bridged peptides; the information here is provided for reference and does not describe any WinHyCare manufacturing or supply activity for this compound.
Typical Quality Specifications
For research and reference-standard grades of AOD-9604, purity is commonly determined by UPLC/HPLC, with the sequence and minor structural variants — including disulfide isomers and deletion sequences — confirmed by LC-MS impurity profiling. Reference-grade material is typically characterised to a high purity (often ≥99.0% by HPLC, with individual impurities controlled below 0.10%) and supported by stability data such as ICH Q1A(R2) long-term and accelerated studies.
A well-defined reference standard is usually characterised for water content, counter-ion (e.g. acetate or trifluoroacetate) content, residual solvents and peptide content, with analytical methods validated to ICH Q2(R1). These specifications are presented as general educational reference for the molecule and reflect typical practice for peptides of this type rather than any specific product offering.
Regulatory & Approval Context
AOD-9604 is not an approved active pharmaceutical ingredient. It is not approved by the FDA, EMA or other major regulators for therapeutic use, and its clinical development as an anti-obesity agent did not lead to approval. As a result it has no marketing authorisation as a finished therapeutic in major jurisdictions.
Where AOD-9604 appears in research, analytical or method-development contexts, it is handled as a research chemical or reference standard rather than as a medicine, and any associated characterisation data (identity, purity, impurity profiling and stability) is used to support analytical qualification and traceability. No efficacy or therapeutic-benefit claims are established for AOD-9604, and the information on this page is educational reference material only.
AOD-9604 API — Specifications
| Compound | AOD-9604 |
|---|---|
| CAS Number | 221231-10-3 |
| Molecular Formula | C78H123N23O23S2 |
| Molecular Weight | 1815.10 g/mol |
| Sequence | 16 amino acids (one intramolecular disulfide bond) |
| Origin | Modified hGH(176-191) C-terminal fragment |
| Drug Class | Modified hGH(176-191) fragment |
| Appearance | White to off-white lyophilised powder |
| Typical Purity (HPLC) | ≥ 99.0% (single impurity < 0.10%) |
| Synthesis Route | Fmoc SPPS + oxidative folding + DAC prep-HPLC |
| Regulatory Status | Not FDA/EMA approved for therapeutic use |
| Form | Lyophilised powder (reference standard) |
Reference data only — WinHyCare neither supplies nor manufactures this compound; see our Semaglutide API for the product we supply. Regulatory status: Not approved by the FDA, EMA or other major regulators for therapeutic use. Clinical development as an anti-obesity agent did not progress to approval.
AOD-9604 API — Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal lipolytic region of human growth hormone — the hGH(177-191) fragment with an additional N-terminal tyrosine residue. Its two cysteine residues form a single intramolecular disulfide bond. It has been studied in preclinical models as a modulator of fat metabolism.
What is the CAS number and molecular weight of AOD-9604?
AOD-9604's CAS number is 221231-10-3, its molecular formula is C78H123N23O23S2, and its molecular weight is approximately 1815.10 g/mol. It is a hexadecapeptide (16 amino acids) with a single intramolecular disulfide bond.
Is AOD-9604 approved?
No. AOD-9604 is not approved by the FDA, EMA or other major regulators for therapeutic use, and its clinical development as an anti-obesity agent did not lead to approval. No efficacy or therapeutic-benefit claims are established for it.
What class of peptide is AOD-9604?
AOD-9604 is a modified hGH(176-191) fragment — a synthetic analogue of the C-terminal region of human growth hormone. It belongs to the growth and metabolism class of peptides and is a short, cysteine-bridged (disulfide-bonded) peptide.
What is AOD-9604 being studied for?
AOD-9604 has been investigated in vitro and in preclinical models as a modulator of adipocyte fat metabolism, where it has been reported to stimulate lipolysis and reduce lipogenesis without the carbohydrate-metabolism effects (such as changes in blood glucose, insulin sensitivity or IGF-1) associated with full-length growth hormone. It was originally explored as a potential anti-obesity agent, though development did not lead to approval.
How is AOD-9604 produced?
AOD-9604 is generally produced by Fmoc solid-phase peptide synthesis (SPPS), followed by controlled oxidative folding to form its single disulfide bond, then preparative dynamic axial compression (DAC) HPLC purification and lyophilisation to a stable powder. This reflects typical industry practice for short, cysteine-bridged peptides.
Related Peptide APIs
Sermorelin API
CAS 86168-78-7
Growth & MetabolismTesamorelin API
CAS 218949-48-5
Growth & MetabolismCJC-1295 API
CAS 863288-34-0
GLP-1 & Incretin Multi-AgonistsSemaglutide API
CAS 910463-68-2
Technical Reference Page
WinHyCare neither supplies nor manufactures AOD-9604; this page is provided as a technical reference. The peptide API we supply is Semaglutide.